Highlights

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of choice for biopharma companies as…

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab20 mg/kg dosed every other week…

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25,…

SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) --…

TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular…

— New Research Demonstrates Multifactorial Beneficial Effects of…

3 May 2023 - Playing Fields, a new original six-part documentary series, introduces the new wave of athletes paving the way in their sports across the African continent – discovering their incredible stories of perseverance, optimism and…

Vabysmo…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 11,…